Vical, Inc.

VICL NASDAQ
0.7225
-0.0285
-3.79%
After Hours: 0.7380 +0.0155 +2.15% 16:30 07/18 EDT
Open
0.7510
Prev Close
0.7510
High
0.7560
Low
0.7200
Volume
309.44K
Avg Vol (3M)
211.70K
52 Week High
1.470
52 Week Low
0.7200
% Turnover
1.35%
Market Cap
16.50M
1D
5D
1M
3M
1Y
5Y

Related

Webull offers Vical, Inc. VICL stock price, real time market quotes, professional analyst ratings, and in-depth charts, You can share investing ideas in community to communicate with others and learn trading skills.

Company Profile

Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
MORE >

Recently

Name
Price
%Change